PTCT
Ptc Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$59.97Close
$4.9BMarket cap
$59.24 – $89.5552-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 23 · weaker than 77% of stocks over 12 months
- Far from its high 33% below its 52-week high
- Earnings shrinking EPS −439% year on year
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
down 1.0%
price change
1mo
down 7.4%
price change
12-month return
down 12%
market up 11% ·
its own down 22%
F-score
—
— Not assessed
Altman Z
1.64
Elevated risk
P/E
7.2×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 22.2%
EBIT / enterprise value
Cheaper than
96%
of the market · markedly cheap
Revenue growth
up 115%
year on year
EPS growth
down 439%
latest quarter
Sales growth
up 70%
latest quarter · -32 pts
ROE
—
return on equity
Free cash margin
up 41%
$702.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.1×
net cash
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-114M → $702M)
- Revenue reaccelerating (-14% then +115%)
Trade setup
ATR%
4.0%
$2.39 a day · 2×ATR $55.19
RS
23 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
2.2×
vs 50-day average
Up/down volume
0.70
50 sessions
Implied move
—
no scheduled report
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$205.3M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 4.9% over the year, from 78m to 81m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 29, 2026
Last shock
Jul 31, 2026-10% in one session2.1× volumeon results-12% since
Financials
- Net 39%
- Free cash 41%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.7B |
| Operating income | -$431.8M | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $866.9M |
| Net income | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $683.0M |
| Net margin | -115% | -97% | -80% | -67% | -45% | 39% |
| Earnings per share | -$6.64 | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.73 |
| Free cash flow | -$211.9M | -$279.5M | -$388.7M | -$186.9M | -$114.2M | $702.3M |
| Free cash margin | -56% | -52% | -56% | -20% | -14% | 41% |
| Cash | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M |
| Long-term debt | $309.1M | $281.9M | $571.7M | $284.2M | $285.4M | — |
| Shareholders' equity | $482.0M | $1.4M | -$347.1M | -$818.6M | -$1.1B | -$205.3M |
| Shares outstanding | 69.72m | 70.83m | 73.10m | 75.71m | 77.70m | 81.47m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Regulation FD ↗ |
| Sep 21, 2026 | Regulation FD · Other events ↗ |
| Aug 28, 2026 | Material agreement ↗ |
| Aug 13, 2026 | Regulation FD · Other events ↗ |
| Jul 30, 2026 | Results · Director or officer change · Regulation FD ↗ |
| Jun 18, 2026 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| Jun 16, 2026 | Other events ↗ |
| Jun 9, 2026 | Director or officer change ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Apr 28, 2026 | Regulation FD ↗ |
| Mar 25, 2026 | Director or officer change · Regulation FD ↗ |